NGS studies have shown that LIF/LIFR are highly expressed in highly prevalent solid tumors, including stomach, pancreas, colon, liver and breast, and we and others have reported that high levels of LIF/LIFR associate with poor prognosis in GC patients and metastasis [20]. Here, LIF is linked to gastric cancer.